Arcturus Therapeutics Holdings, Inc. (ARCT)
12.81
-0.93
(-6.77%)
USD |
NASDAQ |
Oct 12, 12:21
Arcturus Therapeutics Holdings Free Cash Flow (Quarterly) : -20.92M for June 30, 2026
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -20.92M |
| March 31, 2026 | -19.44M |
| December 31, 2025 | -17.99M |
| September 30, 2025 | -19.82M |
| June 30, 2025 | -5.926M |
| March 31, 2025 | -35.28M |
| December 31, 2024 | -0.4617M |
| September 30, 2024 | -23.91M |
| June 30, 2024 | -30.17M |
| March 31, 2024 | -5.797M |
| December 31, 2023 | -1.382M |
| September 30, 2023 | -32.55M |
| June 30, 2023 | 50.23M |
| March 31, 2023 | -36.56M |
| December 31, 2022 | 151.53M |
| September 30, 2022 | -42.55M |
| June 30, 2022 | -34.47M |
| March 31, 2022 | -51.15M |
| December 31, 2021 | -46.33M |
| September 30, 2021 | -18.91M |
| June 30, 2021 | -33.48M |
| March 31, 2021 | -43.07M |
| December 31, 2020 | -8.128M |
| September 30, 2020 | -16.98M |
| June 30, 2020 | -8.925M |
| Date | Value |
|---|---|
| March 31, 2020 | -12.00M |
| December 31, 2019 | -8.012M |
| September 30, 2019 | -3.006M |
| June 30, 2019 | 9.098M |
| March 31, 2019 | -5.489M |
| December 31, 2018 | -5.692M |
| September 30, 2018 | -6.840M |
| June 30, 2018 | -8.331M |
| March 31, 2018 | -0.723M |
| December 31, 2017 | 9.854M |
| September 30, 2017 | -1.401M |
| June 30, 2017 | -4.217M |
| March 31, 2017 | -4.965M |
| December 31, 2016 | -3.942M |
| September 30, 2016 | -6.741M |
| June 30, 2016 | -4.210M |
| March 31, 2016 | -4.46M |
| December 31, 2015 | -4.245M |
| September 30, 2015 | -5.515M |
| June 30, 2015 | -4.000M |
| March 31, 2015 | -4.607M |
| December 31, 2014 | -6.014M |
| September 30, 2014 | -9.307M |
| June 30, 2014 | -5.539M |
| March 31, 2014 | -5.678M |
Free Cash Flow Definition
Free Cash Flow is the cash a company has left after paying for its day-to-day operations and investing in its physical assets, such as buildings, equipment and technology. The company can use that cash however it chooses: paying dividends, buying back shares, paying down debt, making acquisitions or keeping it for future growth.
Free Cash Flow (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 95.69M |
| Emergent BioSolutions, Inc. | 54.00M |
| Exelixis, Inc. | 300.92M |
| Ionis Pharmaceuticals, Inc. | 547.30M |
| United Therapeutics Corp. | 202.20M |